Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study

KAMEN A TSVETANOV,^{1,2,*} LENNART R B SPINDLER,^{1,3} EMMANUEL A STAMATAKIS,^{1,3,4} VIRGINIA FJ NEWCOMBE,^{3,4} VICTORIA C LUPSON,^{3,4} DORIS A CHATFIELD,³ ANNE E MANKTELOW,³ JOANNE G OUTTRIM,³ ANNE ELMER,⁵ NATHALIE KINGSTON,^{6,7} JOHN R BRADLEY,^{7,8} EDWARD T BULLMORE,^{9,†} JAMES B ROWE,^{1,10,†} DAVID K MENON,^{3,4,5,†} AND THE CAMBRIDGE NEUROCOVID GROUP,^a THE NIHR COVID-19 BIORESOURCE,^b THE CAMBRIDGE NIHR CLINICAL RESEARCH FACILITY,^c AND THE CITIID-NIHR BIORESOURCE COVID-19 COLLABORATION^d

^a Cambridge NeuroCOVID Group: Anwar F, Allinson K, Bhatti J, Bullmore ET, Chatfield DA, Christmas D, Coles AJ, Coles JP, Correia M, Das T, Fletcher PC, Jubb AW, Lupson VC, Manktelow AE, Menon DK, Michell A, Needham EJ, Newcombe VFJ, Outtrim JG, Pointon L, Rodgers CT, Rowe JB, Rua C, Sithole N, Spindler LRB, Stamatakis EA, Taylor J, Valerio F, Widmer B, Williams GB.

^b NIHR COVID-19 BioResource⁶: Kingston N, Graves B, Le Gresley E, Caputo D, Stark H, Townsend P, Stirrups KE, Chinnery PF, Bradley JR.

^c NIHR Cambridge Clinical Research Facility: Saunders C, Elmer A

^d CITIID-NIHR BioResource COVID-19 collaboration: Baker S, Bradley JR, Dougan G, Hess C, Goodfellow I, Gupta R, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Oweland WH, Saunders C, Smith KGC, Summers C, Thaventhiran JED, Toshner M, Weekes MP.

* Corresponding author (kat35@cam.ac.uk, +44 1223 766 556)

† Equal contributions

¹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

² Department of Psychology, University of Cambridge, Cambridge, UK.

³ Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.

⁴ Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

⁵ Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

⁶ NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.

⁷ Department of Haematology, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

⁸ Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

⁹ Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

¹⁰ Medical Research Council Cognition and Brain Sciences Unit, Department of Psychiatry, Cambridge, UK.

Abstract:

Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.

Keywords (up to five): *cerebrovascular, microvascular, cardiorespiratory, neurology, COVID-19, SARS-CoV-2*

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes human coronavirus disease 2019 (COVID-19) with multi-system effects that include neurological, vascular and neurovascular injury. Acute neurological sequelae are common, ranging from mild dizziness, headaches and anosmia to severe encephalitis, stroke and delirium (Chen et al., 2020; Hensley et al., 2021; Paterson et al., 2020; Zubair et al., 2020). These sequelae may arise from systemic physiological insults (e.g. hypoxia, hypotension, dysautonomia), coagulation dysfunction, large vessel occlusion, arterial stiffness, impaired vasoreactivity, neurotropic infection, parenchymal haemorrhage, or autoimmune responses against diverse antigens (Chen et al., 2020; Marcic et al., 2021; Mohkhedkar et al., 2021; Schnaubelt et al., 2021). Acute COVID-19 has also been associated with microvascular injury from vasculitis or endothelialitis (Becker, 2020; McGonagle et al., 2021), with endotheliopathy (Kakarla et al., 2021), vasogenic oedema and microthrombosis in the acute phase (Iba et al., 2020; Levi et al., 2020) and hypoperfusion in subacute phase (Hosp et al., 2021). While this acute pathophysiology is detectable using neuroimaging (Hanafi et al., 2020; Lersy et al., 2021; Newcombe

et al., 2020), the persistence and effects of cerebrovascular dysfunction over the medium- and long-term remain unknown.

An important aspect of cerebrovascular function is the capacity of cerebral vessels to constrict or dilate in response to physiological conditions such as alterations in carbon dioxide (CO₂) and oxygen tension. This cerebrovascular reactivity (Willie et al., 2014) regulates regional blood flow via pH-dependent modulation of vascular smooth muscle tone (Ainslie et al., 2005; Jensen et al., 1988; Lambertsen et al., 1961; Lassen, 1968), but is compromised by arterial stiffness, compromised endothelial function (Brandes et al., 2005), or disorders including hypertension, traumatic brain injury and dementia. Poor cerebrovascular reactivity may also increase the risk of neurodegeneration (Gao et al., 2013).

We therefore assessed the impact of COVID-19 on chronic cerebrovascular reactivity after hospitalisation. We use a well-established non-invasive imaging method, exploiting naturally occurring fluctuations in arterial CO₂ induced by variations in cardiac and respiratory cycles, which moderate the blood oxygenation level-dependent (BOLD) signal underlying functional magnetic resonance imaging (Birn et al., 2006; Glover et al., 2007). The BOLD signal variability at rest, known as resting state fluctuation amplitudes (RSFA) is a safe, scalable and robust alternative to the gold standard approaches (Kannurpatti and Biswal, 2008; Tsvetanov et al., 2020c, 2015). It is easier and safer to apply in clinical cohorts than experimental hypercapnia, breath-holding and drug interventions (Keyeux et al., 1995; Rostrup et al., 1996, 1994; Wagerle and Mishra, 1988). RSFA is sensitive to cerebrovascular and cardiovascular differences in ageing (Garrett et al., 2017; Tsvetanov et al., 2020b, 2015), small vessel disease (Makedonov et al., 2013), stroke (Nair et al., 2017; Raut et al., 2016), Alzheimer's disease (Makedonov et al., 2016; Millar et al., 2020a), cognitive performance (Liu et al., 2021; Millar et al., 2021, 2020b) and the presence of brain tumours (Agarwal et al., 2019, 2017).

We report on the chronic effect of COVID-19 on RSFA as a marker of cerebral microvascular function, in relation to acute severity. Exploratory analyses examine the relationship to normative regional variations in neurotransmitters/receptors, brain energy consumption and cell-type distributions. Acute disease severity was quantified by the COVID-19 WHO Progression Scale and blood biomarkers in patients hospitalised for COVID-19. We predicted that acute COVID-19 changes regional RSFA at follow up, in proportion to acute disease severity, over and above the effects of residual systemic cardiorespiratory impairment.

2. Methods

2.1. Participants

Patients were recruited through the NIHR COVID-19 BioResource, which received ethical approval from East of England - Cambridge Central Research Ethics Committee (REC 17/EE/0025), and provided written informed consent. Eligibility was based on admission to Addenbrookes Hospital with COVID-19 between 10th March 2020 and 31st July 2020, aged 18 years or older, survived the acute illness, and attended for a follow up visit, and no contradictions to MRI. 489 patients were potentially eligible. Clinical data were obtained from inpatient electronic medical records, and from cardiorespiratory and neurological assessment at follow-up clinical and research visits at least 6 weeks following symptom onset. 45 patients consented to participate, with clinical, structural and functional resting state functional magnetic resonance imaging (fMRI) data of appropriate quality (see below). Age and sex matched controls were scanned with the same sequences, with data pooled over sequential cohorts to match demographics (Cambridgeshire Research Ethics Committee 97/290 and REC 17/EE/0025, and Norfolk EE/0395 and a protocol approved by the Human Biology Ethics Committee of the Council of the School of Biological Sciences, University of Cambridge). The study and their processing pipelines are summarised in SI Figure 1.

2.2. Inpatient data: COVID-19 severity

The WHO COVID-19 11-point Progression scale was used to provide a measure of disease severity with scores from 0 (non-infected) to 10 (dead) (see Figure 1 in Marshall et al., 2020). We also used blood biomarkers previously associated with COVID-19 severity including the most extreme values during hospitalisation on haematological (lowest platelets) (Wool and Miller, 2021), inflammatory (C-reactive protein, CRP, serum ferritin) (Luan et al., 2021), immunological (interleukin-6, IL-6) (Group et al., 2021a; Ulhaq and Soraya, 2020), hepatic (bilirubin) (Bangash et al., 2020) and coagulatory (D-dimer, prothrombin time (PT) and activated partial thromboplastin time (APTT)) (Asakura and Ogawa, 2020; Iba et al., 2020; Levi et al., 2020). Details of laboratory assay methods used are provided in the Supplementary section. All blood-based measurements were log-transformed to transform the skewed data to approximately conform to normality. For consistency in interpreting scores across blood samples, platelets values were inverted (iPlatelets) so that higher scores represent lower count.

2.3. Clinical visit: cardiorespiratory assessment

Cardiorespiratory measurements were collected during a clinical assessment at least 12 weeks after discharge from initial hospitalization with COVID-19. Systolic and diastolic blood pressure (BPS and BPD) were measured in lying (or seated) and standing position using automated sphygmomanometry using GE Carescape V100 Dinamap Vital Signs Monitor (GE Healthcare Systems, Chicago, Illinois, USA). We calculated pulse pressure (BPS-BPD) and orthostatic hypotension (e.g. BPS lying – BPS standing). Lying and standing pulse pressure values were log-transformed to transform the skewed data to approximately conform to normality.

Lung function was assessed via CareFusion Micro 1 Handheld Spirometer (Vyairre Medical GmbH.; Hoechenberg, Germany) to determine peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio. Measurements were repeated in triplicate, with one minute rest between measurements. Each variable was log-transformed to approximately conform to normality. To balance the representativeness of each data type in the imputations and data-reduction stages (see Supplementary Method), spirometry measures were reduced to a single variable using principal components analyses (SI Figure 2).

Pulse oximetry, monitored via GE Carescape V100 Dinamap Vital Signs Monitor (GE Healthcare Systems, Chicago, Illinois, USA), was used to determine the heart rate and arterial oxygen saturation before and following a 6-minute walk test (Bois et al., 2012; Crapo et al., 2012; PL et al., 2003).

2.4. Research visit: neurological assessment

2.4.1. Image acquisition and pre-processing

Imaging data were acquired using a 3T Siemens Prismafit System with a 32-/20-channel head-coil at the Wolfson Brain Imaging Centre (WBIC; www.wbic.cam.ac.uk) during a research visit. A 3D-structural MRI was acquired on each participant using T1-weighted sequence (3D Magenitisation-Prepared Rapid Gradient-Echo, 3D MPRAGE) with the following parameters: repetition time (TR) = 2 ms; echo time (TE) = 2.99 ms; inversion time (TI) = 880 ms; flip angle $\alpha = 9^\circ$; field of view (FOV) = 208 × 256 × 256 mm³; resolution = 1 mm isotropic; accelerated factor (in-plane acceleration iPAT) = 2; acquisition time, 5 min. T1 images were pre-processed using functions from SPM12 (Wellcome Department of Imaging Neuroscience, London, UK) in Matlab 2020b (Mathworks, <https://uk.mathworks.com/>). The T1 image was rigid-body coregistered to the MNI template, and segmented to extract probabilistic maps of six tissue classes: gray matter (GM), white matter (WM), CSF, bone, soft tissue, and residual noise.

RSFA was estimated from resting state Echo-Planar Imaging (EPI) of 477 volumes acquired with 64 slices for whole brain coverage (TR = 735ms; TE = 30ms; FOV = 210mm x 210mm; resolution = 2.38 x 2.38 x 2.4mm) during 5 minutes and 51 seconds. Participants were instructed to lay still, to stay away and keep their eyes open, looking at a fixation cross. EPI data preprocessing included the following steps: (1) temporal realignment of slices to (0,0,0) Montreal Neurological Institute (MNI) coordinates, (2) spatial realignment to adjust for linear head motion, (3) subjected to Artifact detection tools (ART)-based identification of outlier scans for scrubbing (4) coregistration to the T1 anatomical image from above, (4) application of the normalization parameters from the T1 stream above to warp the functional images into MNI space. We applied whole-brain independent component analysis of single-subject time series denoising to minimise motion artefacts using a priori heuristics using the ICA-based Automatic Removal of Motion Artifact toolbox (AROMA; Pruim et al., 2015a, 2015b) after smoothing with an 6mm FWHM Gaussian kernel.

The initial six volumes were discarded to allow for T1 equilibration. We quantified participant motion using the root mean square volume-to-volume displacement as per Jenkinson et al (2002). A general linear model (GLM) of the time-course of each voxel was used to further reduce the effects of noise confounds (Geerligs et al., 2017), with linear trends and expansions of realignment parameters, plus average signal in WM and CSF, CompCorr regressors, their derivative and quadratic regressors (Satterthwaite et al., 2013). The WM and CSF signal was created by using the average across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps available in SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine transform set in the GLM, ensuring that nuisance regression and filtering were performed simultaneously (Hallquist et al., 2013; Lindquist et al., 2019). Finally, we calculated subject specific maps of RSFA based on the normalized standard deviation across time for processed resting state fMRI time series data (Tsvetanov et al., 2020b). RSFA maps were smoothed by a 12 mm FWHM Gaussian kernel.

To facilitate integrative multivariate analysis (see below), the RSFA maps were parcellated by a prior cortical template into 360 bilaterally symmetric regions (Glasser et al., 2016). Regional RSFA values were estimated by averaging over all voxels in each parcel.

2.4.2. Quality of life, cognition, and mental health

Quality of life, cognition and mental health were assessed using a set of questionnaires: Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Patient Health Questionnaire-15 (PHQ-15), Posttraumatic Stress Disorder Checklist-5 (PCL-5) and subscores from the Short Form-36 (SF-36). SF36 subscores were defined as physical functioning (SF36-PF), role limitation

physical (SF36-RLP), role limitation emotional (SF36-RLE), energy dimension (SF36-ED), emotional wellbeing (SF36-EW), social functioning (SF36-SF), pain (SF36-P) and general health (SF36-GH).

Cognitive function and functional independence were evaluated using Montreal Cognitive Assessment (MoCA, Nasreddine et al., 2005), inverted Modified Ranking Scale (mRS, Eriksson et al., 2007), and Barthel Index (BI, Mahoney and Barthel, 1965). For consistency in interpreting scores across questionnaires, scores for mental health questionnaires were inverted (iGAD-7, iPHQ-9, iPHQ-15 and iPCL-5) so that lower values represent greater mental health problems.

2.5. Analytical approach

Statistical analysis used Matlab 2020b calling the packages as described below. We performed a descriptive analysis of all the characteristics from inpatient, clinical and cognitive data before integrating it with neuroimaging data as described below.

2.5.1. Group differences in cerebral microvascular health

We performed component-based analysis, Source-Based Cerebrovasculometry (Supplementary Material) to determine spatially non-overlapping RSFA maps without using group information. Subject scores for each component was predicted by group identity (Patient vs Control), age, and sex in a subsequence robust multiple linear regression. The model's formula was specified by Wilkinson's notation, 'rsfa ~ group*age + sex' and fitted for each component separately.

2.5.2. COVID-19 severity predicting RSFA

The predictive specificity of COVID-19 severity on RSFA abnormality was tested using a multivariate approach. We adopted a two-level procedure (Passamonti et al., 2019a; Tsvetanov et al., 2020a, 2018, 2016). In the first-level analysis, the relationships between COVID-19 Severity and RSFA data were identified using partial least squares (Krishnan et al., 2011). Partial least squares described the linear relationship between the two multivariate data sets, namely RSFA maps and COVID-19 Severity data by providing pairs of latent variables (RSFA-LV) and (COVID-19 Severity-LV) as linear combinations of the original variables that were optimized to maximize their covariance. Data set 1 consisted of parcellated RSFA maps across all patients (45 patients x 360 nodes array, RSFA dataset). Data set 2 included the COVID-19 WHO Progression scale and inpatient blood data (45 subjects x 9 measures array, COVID-19 Severity datasets). All variables were z-scored (mean of 0 and standard deviation of 1) before entering to a permutation-based PLS analysis with 10.000 permutations to determine the significance of the latent variables.

Next, we tested whether the identified relationship between COVID-19 Severity-LV and RSFA-LV could be explained by other variables of interest and variables of no interest. To this end, we performed a second-level analysis using robust multiple linear regression and commonality analysis (Kraha et al., 2012; Nimon et al., 2008a). Commonality analysis partitions the variance explained by all predictors in MLR into variance unique to each predictor and variance shared between each combination of predictors. Therefore, unique effects indicate the (orthogonal) variance explained by one predictor over and above that explained by other predictors in the model, while common effects indicate the variance shared between correlated predictors. Notably, the sum of variances, also known as commonality coefficients, equals the total R² for the regression model. We adapted a commonality analysis algorithm (Nimon et al., 2008b) implemented in Matlab (Wu et al., 2021). This model aimed to test whether the relationship between COVID-19 Severity and RSFA can be explained partly or fully by systemic cardiorespiratory dysfunction or other covariates of no interest. Predictor variables included subject COVID-19 Severity scores from the first level PLS and systemic cardiorespiratory dysfunction (CRDPC1 and CRDPC2). The dependent variable was subjects' RSFA scores from the first level PLS. Covariates of no interest included age and sex. The model can therefore identify unique variance explained by each of the predictors i.e. whether COVID-19 Severity LV predicts RSFA-LV over and above other predictors. Common effects of interest were the cardiorespiratory-related effects, defined by the common variance between COVID-19 Severity and CRDPCA1-2. Significant effects of interest were identified with nonparametric testing using 10,000 permutations using commonality analysis implementation in Matlab (Wu et al., 2021).

2.5.3. Exploratory analysis

In an exploratory analysis, the level of RSFA abnormalities was related to component measures of physical, cognitive, and mental functioning (PCM) using robust regression. The PCM components, defined by principal component analysis (SI Methods), we defined as dependent variables in separate models. RSFA, age and sex were entered as predictors. The model's formula was specified by Wilkinson's notation, 'PCM ~ RSFA + age + sex' and fitted for each PCM component separately.

We further assessed the spatial overlap between COVID-19-related cerebrovascular burden maps and a range of brain metabolic, neurotransmitter, protein expression and cell-type parameters, including i) existing receptor/metabolic templates and ii) gene transcription profiling maps. Templates of interest included metabolic rates of glucose, oxygen, and aerobic glycolysis (Vaishnavi et al., 2010) and receptor and transmitter maps across nine different neurotransmitter systems (Hansen et al., 2021b), all measured by positron emission tomography (PET). Gene expression maps (Hawrylycz et

al., 2012) were based on key proteins implicated in SARS-Cov-2 cellular attachment (angiotensin converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2), processing (cathepsin-B, CTSB; cathepsin-L, CTSL) and viral defence (interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-family member E, LY6E) (Iadecola et al., 2020; Yang et al., 2021). Spatial correlations were evaluated using spin-based permutations preserving spatial autocorrelation (spin-permutation test) (Alexander-Bloch et al., 2018; Fulcher et al., 2021).

Spatial covariance between the cerebrovascular burden map and gene expression across 9394 genes expressed in the human brain (Hawrylycz et al., 2012) was based on regularized-PLS association (Blankertz et al., 2011; Ledoit and Wolf, 2004) using spin-premutation-based 10-fold cross-validations (Tsvetanov et al., 2020a). The latent variable represented a spatial pattern of gene expression that highly covaries with the cerebrovascular burden pattern associated with COVID-19 severity. Full details about the processed transcriptomic data are available elsewhere (Arnatkevičiūtė et al., 2019). Genes highly expressing this pattern (i.e. high loadings) were tested against a molecular atlas of human brain vasculature of 17 control and Alzheimer's disease patients (Yang et al., 2021) using cell-type decomposition approach (Hansen et al., 2021a). This enabled us to test whether the cerebrovascular burden-relevant genes are preferentially expressing in specific cell types i.e. testing for cell-specific aggregate gene sets in eleven major canonical cortical cell classes: astrocytes (Astro); brain endothelial cells (BEC); ependymal (Epend); macrophage/microglia (MacMic); meningeal fibroblast (MFibro); neuron (Neuro); oligodendrocyte precursors (Opc); oligodendrocytes (Oligo); pericytes (Peri); perivascular fibroblast (PFibro); smooth muscle cells (SMC). To this end, we calculated the ratio of genes in each set preferentially expressed in each cell type (e.g. ratio for pericytes is calculated from the number of genes preferentially expressed in pericytes divided by the total number of genes). Gene sets were thresholded to include the top $n\%$ of genes with greatest loadings, where n varied from 5% to no threshold. Statistical significance was determined using a null distribution of ratios based on 10.000 sets of random genes (Hansen et al., 2021a).

2.6. Data availability and code

Code and composite data to reproduce manuscript figures, statistical analyses are available at https://github.com/kamentsvetanov/covid19_cerebrovascularburden. Resting-state fMRI data was pre-processed using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm>; Friston et al., 2007) and post-processed using a GLM-like approach (Geerligs et al., 2017) available at <https://github.com/MRC-CBU/riksneurotools/blob/master/GLM/>. MATLAB-based commonality analysis for neuroimaging is available at <https://github.com/kamentsvetanov/CommonalityAnalysis/>. Visualisation of

neuroimaging results was in MRlcroGL (<https://github.com/rordenlab/MRlcroGL>; Rorden and Brett, 2000) and BrainSpace (Vos de Wael et al., 2020). Neurotransmitter receptor and transporter maps were available at https://github.com/netneurolab/hansen_receptors. Spin permutations (Váša et al., 2018) used code available at https://github.com/frantisekvasa/rotate_parcellation. Fully-pre-processed transcriptomic data was available at <https://figshare.com/articles/dataset/AHBAdata/6852911> and <https://github.com/BMHLab/AHBAProcessing>. The molecular atlas of the human brain vasculature was available at <https://www.biorxiv.org/content/10.1101/2021.04.26.441262v1>. Cell-type decomposition analysis related code was available at https://github.com/netneurolab/hansen_genescognition.

3. Results

3.1. Participants

Characteristics of the 45 patients hospitalized with COVID-19 are detailed in Table 1. At hospitalisation, 30% of the patients required a mechanical ventilation (n=13) for an average of 20 days; 22% of patients required vasopressors (n=10), and 9% renal replacement therapy with continuous veno-venous haemodiafiltration (n=4). The average number of days from initial symptoms to clinical and research visit was 169±35 and 180±58, respectively. Data missingness is detailed in Supplementary Results.

Table 1. Characteristics of 45 patients hospitalised with COVID-19. n - indicates number of patients and the percentage of patients from the patient cohort (%), SD – standard deviation, IQR – interquartile range, kg – weight in kilograms, m – height in meters.

Variable	n (%)	Mean(SD)/Median(IQR)*
Age (years)	45 (100)	52 (14)
Education (years)	45 (100)	16 (4)
Female	26 (58)	-
Right-handed	40 (89)	-
Inpatient data		
Vasopressors	10 (22)	-
Dialysis	4 (9)	-
BMI (kg/m ²)	36 (80)	29 (4)
Mechanical Ventilation (days)	13 (29)	20 (15)
CRP	42 (93)	149 (147)
D Dimer	37 (82)	1125 (2071)
Ferritin	32 (71)	1225 (1700)
IL-6	28 (62)	39 (80)
PT	32 (71)	26 (54)
APTT	33 (73)	42 (36)
Bilirubin	43 (96)	14 (8)
Platelets	44 (98)	230 (102)
Clinical Visit		
HR (bpm)	38 (84)	76 (14)
RR (cpm)	38 (84)	16 (2)
SBP lying (mmHg)	38 (84)	134 (23)
SBP standing (mmHg)	33 (73)	130 (20)
DBP lying (mmHg)	38 (84)	74 (12)
DBP standing (mmHg)	33 (73)	79 (11)
Research Visit		
GAD-7 (0-21)	44 (98)	4 (8)*
PHQ-9 (0-27)	44 (98)	7 (9)*
PHHQ-15 (0-30)	39 (87)	9 (8)*
PCL-5 (0-80)	44 (98)	16 (22)*
MoCA	39 (87)	28 (3)*
mRS	39 (87)	1 (1)*
BI	37 (82)	20 (0)*
Initial symptoms to Admission (days)	40 (89)	14 (14)
Hospitalisation Duration (days)	40 (89)	19 (31)
Initial symptoms to Clinic visit (days)	39 (87)	169 (35)
Initial symptoms to Research visit (days)	45 (100)	180 (58)

3.2. Group differences in Cerebrovascular components

Using source-based cerebrovasculometry (Passamonti et al., 2019b; Tsvetanov et al., 2020b, 2015; Xu et al., 2009), we assessed the group differences in RSFA-based cerebrovascular components between controls and patients in small set of spatially independent components ($n=8$). Each participant had one value per component, *subject score*, indicating the degree to which a participant expresses the spatial map of the corresponding component. One component showed significant difference between the patient and control group in terms of their subject scores (RSFA_{IC4}, $t = 3.12$, $p = 0.003$, Figure 1), while controlling for age and sex in a robust linear regression. The spatial extent of this component, RSFA_{IC4}, included voxels with high values in temporo-parietal regions, indicating that individuals with higher loading values, in this case the patient group, had lower RSFA values in these regions, relative to the control group (Figure 1). The other components did not differentiate patients from controls (SI Analyses).

The spatial pattern of IC4 was consistent with the univariate approach ($r=0.46$, $p<0.001$, SI Figure 5). In addition, the univariate approach revealed that the spatial pattern in RSFA associated with age was highly consistent with the one reported on large-scale population-based cohorts, $r=0.42$, $p<0.001$ (Tsvetanov et al., 2020b, 2015). This suggests that RSFA can detect reliably differences in cerebrovascular health across various phenotypes in smaller samples. Though age is a risk factor of COVID-19 severity (Verity et al., 2020) and RSFA (Tsvetanov et al., 2020c), the COVID-19 group effect was not explained by individual's age, and showed only a partial overlap with the effects of age on RSFA in parietal regions (SI Figure 5, Tsvetanov et al., 2020b, 2015).

a | Cerebrovascular burden map

b | subject burden expression

Figure 1. Source-based cerebrovasculometry for the component differentially expressed between groups: (left) independent component spatial map reflecting decrease in RSFA values in temporo-parietal regions. (right) Bar plot of subject scores for patients hospitalised for COVID-19 (red) and control group (green, each circle represents an individual) indicating higher loading values for patients than controls as informed by two-sample unpaired permutation test (a robust regression was used to down-weight the effects of extreme data points)

3.3. COVID-19 Severity predicts cerebrovascular impairment

Using PLS analysis, we identified one significant pair of latent variables ($r = 0.584$, $p = 0.017$, based on a null distribution of 10,000 permutations). Variable loadings and subject scores showed a strong relationship between acute COVID-19 Severity and chronic RSFA abnormalities (Figure 2).

The RSFA latent variable (RSFA-LV) expressed negative loadings in frontal (superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus and portions of the anterior cingulate) and parieto-temporal (angular gyrus, supramarginal gyrus, superior temporal gyrus, middle temporal gyrus) regions. This pattern of COVID-19 Severity-related reduction in RSFA values was mirrored in a voxel-wise analysis of RSFA maps and COVID-19 Severity component (SI Figure 5). Positive loadings in the RSFA data appeared to be in postcentral gyrus, calcarine sulcus, cuneus, and lingual gyrus. Increase in the RSFA signal in these regions may reflect increased pulsatility in neighbouring vascular and white matter territories (see SI Figure 5) as reported previously (Makedonov et al., 2016, 2013; Tsvetanov et al., 2020b, 2015). This pair of latent variables suggested that patients with higher COVID-19 Severity at acute stage have poorer cerebrovascular function in frontal and temporo-parietal regions at chronic stage. For visualisation purposes we inverted the loading values in Figure 2a so that higher values reflect poorer cerebrovascular function, i.e. higher cerebrovascular burden.

Figure 2. Partial least squares analysis of COVID-19 severity data at acute stage and RSFA-based cerebrovascular burden (CVB) at chronic stage. (panel a) Spatial distribution of parcellated RSFA values where dark to light colours are used for the strength of positive and negative correlations with the COVID-19 Severity profile (panel c). Note that regions with high cerebrovascular burden have low values in RSFA. The scatter plot in the middle panel represents the relationship between subjects scores of RSFA-latent variable and COVID-19 Severity-latent variable identified by partial least squares analysis.

To understand whether the relationship between regional RSFA impairment and COVID-19 Severity can be explained by chronic systemic cardiorespiratory dysfunction (see SI method) or covariates of no interest, we performed a second level robust regression analysis. RSFA-LV was entered as the dependent variable. COVID-19 Severity LV and the cardiorespiratory dysfunction

component (CRD_{PCA1} , see SI Figure 3) were entered as predictors, while age and sex were modelled as covariates of no interest. All variables were normalised to have a mean of 0 and standard deviation 1. Using Wilkinson notation, the regression model took the form: $RSFA-LV \sim COVID-19\ Severity-LV + CRD_{PCA1} + CRD_{PCA2} + Age + Sex$. COVID-19 Severity was the only significant predictor of RSFA-LV in the model ($r = 0.471$, $p = 0.001$ and SI Table 1), suggesting that chronic cardiorespiratory dysfunction, age and sex cannot explain fully the relationship between COVID-19 Severity and RSFA abnormality. Interestingly, the unique variance explained by COVID-19 Severity in the regression model was weaker than the variance identified by the PLS analysis ($r = 0.584$ vs $r = 0.471$ for PLS and MLR analyses) suggesting that one or more of the predictors in the model explain partly some of the variance between COVID-19 Severity and RSFA. Permutation-based commonality analysis with 10,000 permutations (SI Method) confirmed that a portion of the variance between COVID-19 Severity-LV and RSFA-LV was explained by age (12% total, $p < 0.001$), cardiorespiratory dysfunction component 2 (CRD_{PC2} , 3% total, $p = 0.009$), and shared variance between age and cardiorespiratory dysfunction component 1 (Age, CRD_{PCA1} , 20% total, $p < 0.001$), SI Table 2. COVID-19 Severity-LV remained as the largest unique predictor of RSFA-LV (37% total, $p = 0.006$).

3.4. Exploratory analysis

The level of RSFA abnormalities (RSFA-LV) was related to physical, cognitive and mental functioning in an exploratory analysis. RSFA-LV, age and sex were entered as predictors, while cognitive and mental health components (SI Methods) were used as dependent variables in separate robust regressions (Model 1: $CMH_{PCA1} \sim RSFA-LV + age + sex$; Model 2: $CMH_{PCA2} \sim RSFA-LV + age + sex$). Model 1 was not significant ($p = 0.429$), while Model 2 was significant ($R^2 = 0.294$, $p = 0.002$) with RSFA predicting significantly cognitive and mental health component 2 ($r = -0.352$, $p = 0.014$, SI Table 3). This indicates that patients with higher RSFA abnormality have worse cognitive function, less functional independence and lower quality of life (social functioning, emotional wellbeing, energy dimension). The results did not change in a meaningful way by re-imputing the data ($n=5$). The findings in Model 2 were confirmed using voxel-wise analysis on RSFA maps, instead of RSFA-LV (SI Figure 7).

We next assessed the spatial overlap between COVID-19-related cerebrovascular burden maps with existing neurotransmitter and metabolic maps using spatial autocorrelation-preserving permutation testing (Alexander-Bloch et al., 2018). Across 21 candidate maps, we show that the cerebrovascular burden map overlaps with the distribution of serotonin's vasoactive receptor 5-HT1b, aerobic glycolysis and to a weaker extent cerebral metabolic rate of glucose in the brain. However, the

regional distribution of RSFA abnormality showed little correlation with the expression of key proteins implicated in SARS-CoV-2 cellular attachment, processing and viral defence (Figure 3). Collectively, these results demonstrate that the distribution of cerebrovascular impairment related to COVID-19 severity is aligned with the spatial distribution of receptors and processes involved in the coordination of metabolic and vasoreactive responses.

Figure 3. Spatial correlation between Covid19 severity-induced cerebrovascular burden map and spatial patterns associated with a range of neurotransmitter receptor/transporters (Hansen et al., 2021b), selective genes relevant to SARS-CoV-2 brain entry (Iadecola et al., 2020) and brain metabolism parameters (Vaishnavi et al., 2010). Neurotransmitter receptors and transporters were selective to serotonin (5-HT1a, 5-HT1b, 5-HT2a, 5-HT4, 5-HT6, 5-HTT), norepinephrine (NET), histamine (H3), acetylcholine (ACh, A4B2, M1, VAcHT), cannabinoid (CB1), opioid (MOR), glutamate (mGluR5), GABA (GABAa/bz) and dopamine (D1, D2, DAT). Metabolic maps were based on cerebral blood flow (CBF), cerebral blood volume (CBV), cerebral metabolic rate of glucose and oxygen (CMRGlucose, CMRO2) and glycemic index (GI). Selective genes relevant to SARS-CoV-2 brain entry included angiotensin converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2, cathepsin-B, CTSB; cathepsin-L, CTSL, interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-family member E, LY6E. The spatial maps of 5-HT1b, CMRGlucose and Glycemic Index (GI) were significantly correlated with Covid19 severity-induced cerebrovascular burden map (* p -spin<0.05 (one-sided), *** p -spin<0.001). See text for more information.

As a final step, we used normative transcriptomics to identify genes that are normally preferentially expressed in the regions associated with COVID-19-induced cerebrovascular impairment. Regularised-PLS identified one latent component ($r=.64$, $p=0.001$, Figure 4a). Using cell-type decomposition analysis on a vascular cell-type specific gene sets, we determined the ratio of genes in each gene set preferentially expressed in one of eleven cortical cell types: astrocytes, brain

endothelial cells, ependymal, macrophage/microglia, meningeal fibroblast, neuron, oligodendrocyte precursors, oligodendrocytes, pericytes, perivascular fibroblast, smooth muscle cells. Gene-sets were thresholded to include the top 70% of genes with the highest loadings (Figure 4b), noting that results are consistent across thresholds ranging from 5 to no threshold (Supplementary Figure 8). Dominant genes were significantly more expressed in pericytes, brain endothelial cells and neurons, and significantly less expressed in oligodendrocytes. Broadly, we find evidence that areas associated with cerebrovascular impairment are enriched in for genetic signal related to neuron support (pericytes, endothelial cells and perineuronal oligodendrocytes) and neurons themselves. This dichotomy is consistent with the observations from the spatial overlap analysis.

a | CVB-related transcription map

b | cell-specific expression

Figure 4. **a**, Spatial map in the transcriptome data related to the COVID-19-induced cerebrovascular burden map (CVB). **b**, Cell-type decomposition was used to identify cell-type enrichment based on extent to which genes expressed the transcriptome map in **a**. Gene sets for each cell-type was constructed by thresholding the top 70% of genes with greatest loadings. Note that results were consistent across a range of thresholds, ranging from 10% to no threshold, SI Figure 8. The ratio of genes in each gene set preferentially expressed in eleven distinct cell-types (circles) is shown against their null distribution of a model with random selection of all genes (10,000 permutations, *p-value < 0.05). For example, pericyte's ratio is calculated from the number of genes preferentially expressed in pericytes divided by the total number of genes. Cell type-specificity of genes is described elsewhere (Yang et al., 2021) Astro – astrocytes, BEC – brain endothelial cells, Epend – ependymal, MacMic – macrophage/microglia, Mfibo – meningeal fibroblast, Neuron – neuron, OPC – oligodendrocyte precursor cells, Oligo – oligodendrocytes, Peri – pericytes, Pfibro – perivascular fibroblast, SMC – smooth muscle cells

4. Discussion

We show that abnormalities in cerebral microvascular function, measured using resting state fluctuation amplitudes (RSFA), persist many months after hospitalisation for acute COVID-19. The location of these abnormalities in lateral frontal and temporoparietal regions aligns partly with cerebrovascular dysfunction reported in association with ageing (Tsvetanov et al., 2020b, 2015), preclinical Alzheimer's disease (Millar et al., 2020a) and systemic cardiovascular health (Tsvetanov et

al., 2020b). These post-COVID-19 effects were observed over and above age. They are related to severity of the acute illness and the host response in the acute stage. These effects also relate to the post-COVID-19 cognitive function, common indices of mental health, and quality of life at an average of six months after hospitalisation.

In exploratory analysis, we found overlap between the regional distribution of this cerebrovascular impairment and spatial distribution of the vasoreactive receptor 5-HT_{1b} and regions with high metabolic demands. 5-HT_{1b} receptor is the dominant contractile 5-HT receptor in cerebral arteries (Barnes et al., 2021; Nilsson et al., 1999), acting on vasoconstriction by contracting smooth muscle endothelial smooth muscle directly or as moderator of other vasoconstrictors. Distinct from its effects on vascular tone, the presynaptic 5-HT_{1b} receptor also has an important microvascular anti-inflammatory role, both in the cerebrovascular bed and more generally. Further, its loss has been implicated in progressive cognitive loss and abnormal modulation through descending serotonergic outputs (Gharishvandi et al., 2020; Heijmans et al., 2021; Mitsikostas et al., 2002; Sibille et al., 2007), which may be relevant for late sequelae after COVID-19.

The overlap of cerebrovascular impairment with the regional distribution of aerobic glycolysis and glucose metabolism is spatially concordant with previous reports of hypometabolism in the subacute phase of COVID-19 (Hosp et al., 2021) and neurodegeneration (Vlassenko et al., 2010). This discussion provides a potential link between cerebrovascular impairment and metabolic dysfunction in frontoparietal regions, which could provide important insights regarding the mechanisms of late neurocognitive dysfunction following COVID-19 infection. Future work should establish whether changes to the microvasculature lead to hypometabolism (Shi et al., 2016) or the vulnerability of brain physiology in chronic phase is due to hypoxic and hypometabolic exposure in the subacute phase (Vestergaard et al., 2020). Collectively, these results demonstrate that the distribution of chronic cerebrovascular impairment related to COVID-19 severity maps to the spatial distribution of processes involved in coordinating metabolic and vasoregulatory responses associated with changes in brain function and cognition.

We also tested whether genes highly expressed in regions with COVID-19-induced cerebrovascular change are preferentially expressed in specific cell types using a molecular atlas of human brain vasculature (Yang et al., 2021). Dominant genes were overexpressed in pericytes, brain endothelial cells and neurons, but underexpressed in oligodendrocytes. The evidence that genes implicated are enriched in pericytes and endothelial cells is particularly interesting. Brain endothelial cells are susceptible to direct SARS-CoV-2 infection through flow-dependent expression of ACE2. The SARS-

CoV-2 S protein binding triggers a gene expression profile that may compromise the neurovascular interface (Kaneko et al., 2021). On the abluminal aspect of the neurovascular interface, pericytes express abundantly the angiotensin-converting enzyme-2 (ACE2) receptor (He et al., 2020). The expression can be increased with by exposure to the viral S protein, and importantly, potentiated in combination with hypoxia (Khaddaj-Mallat et al., 2021), a mechanism which could account for the modulation of RSFA abnormality by disease severity in our cohort.

Given this biological context the correlation of RSFA abnormalities with disease severity is open to two potential interpretations. One possibility is that these changes in cerebrovascular regulatory integrity are the consequence of direct viral invasion; while the other is that these abnormalities are a consequence of the inflammatory host response, which is a consequence of, but may not scale precisely with, viral infection. Spatial correlation of RSFA abnormality with the expression of ACE2 and Neuropilin-1, or of genes involved in cellular responses to viral invasion would have provided supportive evidence of a role for direct viral infection as a mechanism, but we were unable to demonstrate such a correlation. This negative finding favours the explanation that host inflammatory responses may be drivers in this context, and merit further investigation as mechanisms of late cerebrovascular regulatory dysfunction. It is important to acknowledge that our correlations with regional gene expression are based on expression patterns in normal brain, and that these expression patterns may be substantially altered by the inflammatory milieu that prevails in the context of COVID-19. Consequently, direct examination gene expression patterns in late COVID-19 survivors would provide additional insights.

Our study has several limitations. We are limited by the relatively small sample size, and by the absence of longitudinal imaging data. We also do not draw any causal inferences from the associations we observe. However, the demonstration of functional microvascular abnormalities following COVID-19 is important to understand the potential mechanisms of persistent cognitive and mental health problems. The association of microvascular abnormalities with late outcomes of relevance to patients, and the fact that they represent an easily accessible biomarker, suggest both a potential therapeutic target and/or a biomarker of treatment effect in interventional studies. It remains to be shown whether the localisation of RSFA abnormalities to regions rich in 5HT-1b receptors is a consequence of overactivity of these receptors (resulting in low cerebral blood flow), underactivity or loss of these receptors (resulting in vasoparalysis and/or inflammation), or a manifestation of flow-metabolism mismatching with inadequate substrate and oxygen delivery. This is relevant as potential therapeutic agents that are available to modulate both 5HT-1b function (Barnes et al 2021) and inflammatory response (Zhang et al., 2020) (Group et al., 2021b; Zhang et al., 2020).

In summary, we demonstrate that the severity of acute COVID-19 predicts cerebrovascular impairment six months later. The cerebrovascular abnormality was associated with worse cognitive function, mental health, functional recovery, and quality of life months after hospitalisation. Localised across lateral frontotemporoparietal regions, we show that its genetic signature shapes the composition of cell-types and metabolism. Collectively, these results implicate the COVID-19-related vulnerability of brain systems differentially relying on diverse physiology and cell biology in support of their functional specialisation.

5. Acknowledgements

This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), NIHR funding to the NIHR BioResource (RG94028 & RG85445), Guarantors of Brain (G101149), Wellcome Trust (220258), Medical Research Council (SUAG/051G101400; and SUAG/010 RG91365), and by the Addenbrookes Charitable Trust. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

6. Conflicts of interest

All authors have no conflicts of interest. Untreated to this there are several disclosures.

VFJN holds a grant from Roche Pharmaceuticals on proteomic biomarkers in traumatic brain injury and reports personal fees from Neurodiem.

ETB serves on the scientific advisory board of Sosei Hepatares and as a consultant for GSK.

JBR serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen, UCB and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK.

DKM reports grants, personal fees, and nonfinancial support from GlaxoSmithKline Ltd.; grants, personal fees, and other from NeuroTrauma Sciences; grants and personal fees from Integra Life Sciences; personal fees from Pfizer Ltd.; grants and personal fees from Lantmannen AB; from Calico Ltd.; personal fees from Pressura Neuro Ltd.; and others from Cortirio Ltd., outside the submitted work.

7. References

- Agarwal, S., Hanzhang, L., Pillai, J.J., 2017. Value of Frequency Domain Resting-State Functional Magnetic Resonance Imaging Metrics Amplitude of Low-Frequency Fluctuation and Fractional Amplitude of Low-Frequency Fluctuation in the Assessment of Brain Tumor-Induced Neurovascular Uncoupling. <https://home.liebertpub.com/brain> 7, 382–389. <https://doi.org/10.1089/BRAIN.2016.0480>
- Agarwal, S., Sair, H., Gujar, S., Hua, J., Lu, H., Pillai, J., 2019. Functional Magnetic Resonance Imaging Activation Optimization in the Setting of Brain Tumor-Induced Neurovascular Uncoupling Using Resting-State Blood Oxygen Level-Dependent Amplitude of Low Frequency Fluctuations. *Brain connectivity* 9, 241–250. <https://doi.org/10.1089/BRAIN.2017.0562>
- Ainslie, P.N., Ashmead, J.C., Ide, K., Morgan, B.J., Poulin, M.J., 2005. Differential responses to CO₂ and sympathetic stimulation in the cerebral and femoral circulations in humans. *The Journal of physiology* 566, 613–24. <https://doi.org/10.1113/jphysiol.2005.087320>
- Alexander-Bloch, A.F., Shou, H., Liu, S., Satterthwaite, T.D., Glahn, D.C., Shinohara, R.T., Vandekar, S.N., Raznahan, A., 2018. On testing for spatial correspondence between maps of human brain structure and function. *NeuroImage* 178, 540. <https://doi.org/10.1016/J.NEUROIMAGE.2018.05.070>
- Arnatkevičiūtė, A., Fulcher, B.D., Fornito, A., 2019. A practical guide to linking brain-wide gene expression and neuroimaging data. *NeuroImage* 189, 353–367. <https://doi.org/10.1016/J.NEUROIMAGE.2019.01.011>

550 Asakura, H., Ogawa, H., 2020. COVID-19-associated coagulopathy and disseminated intravascular
551 coagulation. *International Journal of Hematology* 2020 113:1 113, 45–57.
552 <https://doi.org/10.1007/S12185-020-03029-Y>

553 Bangash, M.N., Patel, J., Parekh, D., 2020. COVID-19 and the liver: little cause for concern. *The Lancet*
554 *Gastroenterology & Hepatology* 5, 529–530. [https://doi.org/10.1016/S2468-1253\(20\)30084-4](https://doi.org/10.1016/S2468-1253(20)30084-4)

555 Barnes, N.M., Ahern, G.P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S.,
556 Cunningham, K.A., Fone, K.C., Gershon, M., di Giovanni, G., Goodfellow, N.M., Halberstadt, A.L.,
557 Hartley, R.M., Hassaine, G., Herrick-Davis, K., Hovius, R., Lacivita, E., Lambe, E.K., Leopoldo, M.,
558 Levy, F.O., Lummis, S.C.R., Marin, P., Maroteaux, L., McCreary, A.C., Nelson, D.L., Neumaier, J.F.,
559 Newman-Tancredi, A., Nury, H., Roberts, A., Roth, B.L., Roumier, A., Sanger, G.J., Teitler, M.,
560 Sharp, T., Villalón, C.M., Vogel, H., Watts, S.W., Hoyer, D., 2021. International Union of Basic and
561 Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology
562 and Function. *Pharmacological reviews* 73, 310–520. <https://doi.org/10.1124/PR.118.015552>

563 Becker, R.C., 2020. COVID-19-associated vasculitis and vasculopathy. *Journal of Thrombosis and*
564 *Thrombolysis* 2020 50:3 50, 499–511. <https://doi.org/10.1007/S11239-020-02230-4>

565 Birn, R.M., Diamond, J.B., Smith, M. a, Bandettini, P. a, 2006. Separating respiratory-variation-related
566 fluctuations from neuronal-activity-related fluctuations in fMRI. *NeuroImage* 31, 1536–48.
567 <https://doi.org/10.1016/j.neuroimage.2006.02.048>

568 Blankertz, B., Lemm, S., Treder, M., Haufe, S., Müller, K.-R., 2011. Single-trial analysis and classification
569 of ERP components--a tutorial. *NeuroImage* 56, 814–25.
570 <https://doi.org/10.1016/j.neuroimage.2010.06.048>

571 Bois, R.M. du, Weycker, D., Albera, C., Bradford, W.Z., Costabel, U., Kartashov, A., Lancaster, L., Noble,
572 P.W., Sahn, S.A., Szwarzberg, J., Thomeer, M., Valeyre, D., Talmadge E. King, Jr., 2012. Six-
573 Minute-Walk Test in Idiopathic Pulmonary Fibrosis. [https://doi.org/10.1164/rccm.201007-](https://doi.org/10.1164/rccm.201007-1179OC)
574 [1179OC](https://doi.org/10.1164/RCCM.201007-1179OC) 183, 1231–1237. <https://doi.org/10.1164/RCCM.201007-1179OC>

575 Brandes, R.P., Fleming, I., Busse, R., 2005. Endothelial aging. *Cardiovascular Research*.
576 <https://doi.org/10.1016/j.cardiores.2004.12.027>

577 Chen, X., Laurent, S., Onur, O.A., Kleineberg, N.N., Fink, G.R., Schweitzer, F., Warnke, C., 2020. A
578 systematic review of neurological symptoms and complications of COVID-19. *Journal of*
579 *Neurology* 2020 268:2 268, 392–402. <https://doi.org/10.1007/S00415-020-10067-3>

580 Crapo, R.O., Casaburi, R., Coates, A.L., Enright, P.L., MacIntyre, N.R., McKay, R.T., Johnson, D., Wanger,
581 J.S., Zeballos, R.J., Bittner, V., Mottram, C., 2012. ATS Statement: Guidelines for the six-minute
582 walk test. <https://doi.org/10.1164/ajrccm.166.1.at1102> 166, 111–117.
583 <https://doi.org/10.1164/AJRCCM.166.1.AT1102>

584 Eriksson, M., Appelros, P., Norrving, B., Terént, A., Stegmayr, B., 2007. Assessment of Functional
585 Outcome in a National Quality Register for Acute Stroke. *Stroke* 38, 1384–1386.
586 <https://doi.org/10.1161/01.STR.0000260102.97954.9C>

587 Friston, K.J., Ashburner, J., Kiebel, S., Nichols, T., Penny, W.D., 2007. Statistical parametric mapping :
588 the analysis of functional brain images. Elsevier Academic Press. [https://doi.org/10.1016/B978-0-](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)
589 [12-372560-8.X5000-1](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)

590 Fulcher, B.D., Arnatkeviciute, A., Fornito, A., 2021. Overcoming false-positive gene-category
591 enrichment in the analysis of spatially resolved transcriptomic brain atlas data. *Nature*
592 *Communications* 2021 12:1 12, 1–13. <https://doi.org/10.1038/s41467-021-22862-1>

593 Gao, Y.-Z., Zhang, J.-J., Liu, H., Wu, G.-Y., Xiong, L., Shu, M., 2013. Regional cerebral blood flow and
594 cerebrovascular reactivity in Alzheimer’s disease and vascular dementia assessed by arterial
595 spinlabeling magnetic resonance imaging. *Current neurovascular research* 10, 49–53.

596 Garrett, D.D., Lindenberger, U., Hoge, R.D., Gauthier, C.J., 2017. Age differences in brain signal
597 variability are robust to multiple vascular controls. *Scientific Reports* 7, 10149.
598 <https://doi.org/10.1038/s41598-017-09752-7>

599 Geerligs, L., Tsvetanov, K.A., Cam-Can, Henson, R.N., 2017. Challenges in measuring individual
600 differences in functional connectivity using fMRI: The case of healthy aging. *Human Brain*
601 *Mapping*. <https://doi.org/10.1002/hbm.23653>

602 Gharishvandi, F., Abdollahi, A., Shafaroodi, H., Mohammad Jafari, R., Pasalar, P., Dehpour, A.R., 2020.
603 Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in
604 intestinal ischemia/reperfusion in rats. *European journal of pharmacology* 882.
605 <https://doi.org/10.1016/J.EJPHAR.2020.173265>

606 Glasser, M.F., Coalson, T.S., Robinson, E.C., Hacker, C.D., Harwell, J., Yacoub, E., Ugurbil, K.,
607 Andersson, J., Beckmann, C.F., Jenkinson, M., Smith, S.M., Van Essen, D.C., 2016. A multi-modal
608 parcellation of human cerebral cortex. *Nature* 2016 536:7615 536, 171–178.
609 <https://doi.org/10.1038/nature18933>

610 Glover, G.H., Shmueli, K., van Gelderen, P., de Zwart, J. a, Horovitz, S.G., Fukunaga, M., Jansma, J.M.,
611 Duyn, J.H., 2007. Low-frequency fluctuations in the cardiac rate as a source of variance in the
612 resting-state fMRI BOLD signal. *NeuroImage* 38, 306–20.
613 <https://doi.org/10.1016/j.neuroimage.2007.07.037>

614 Group, T.W.R.E.A. for C.-19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M.,
615 Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E.,
616 Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J.,
617 Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J.,

618 Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci,
619 A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M.,
620 Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols,
621 H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, A.-K.,
622 Aleman, S., Sönnernborg, A., Henter, J.-I., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi,
623 Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng,
624 A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R.,
625 Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D.,
626 McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R.,
627 Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A.,
628 Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K.,
629 Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M.,
630 Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L.,
631 Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,
632 Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte,
633 Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C.,
634 SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G.,
635 BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G.,
636 AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE,
637 L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA,
638 O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G.,
639 SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O.,
640 Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J.,
641 Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F.,
642 Pourchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S.,
643 Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes,
644 R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A.,
645 Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L.,
646 Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L.,
647 Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M.,
648 Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N.,
649 Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H.,
650 Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S.,
651 Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO,

J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C., Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J., Strek, M., Adegunsoye, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B., Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F., Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B., Colman, R., Buyser, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T., Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby, P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E., Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A., Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers, A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohbehn, G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van, Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021a. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 326, 499–518. <https://doi.org/10.1001/JAMA.2021.11330>

Group, T.W.R.E.A. for C.-19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M., Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E., Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J., Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J., Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci, A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M., Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols, H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, A.-K., Aleman, S., Sönnernborg, A., Henter, J.-I., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi, Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng, A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R., Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D., McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R., Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A., Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K., Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M., Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L., Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,

686 Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte,
687 Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C.,
688 SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G.,
689 BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G.,
690 AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE,
691 L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA,
692 O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G.,
693 SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O.,
694 Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J.,
695 Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F.,
696 Pourchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S.,
697 Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes,
698 R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A.,
699 Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L.,
700 Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L.,
701 Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M.,
702 Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N.,
703 Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H.,
704 Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S.,
705 Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO,
706 J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C.,
707 Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J.,
708 Strek, M., Adegunsoye, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B.,
709 Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F.,
710 Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B.,
711 Colman, R., Buyser, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T.,
712 Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby,
713 P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E.,
714 Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A.,
715 Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers,
716 A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohhahn,
717 G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van,
718 Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021b.
719 Association Between Administration of IL-6 Antagonists and Mortality Among Patients

Hospitalized for COVID-19: A Meta-analysis. *JAMA* 326, 499–518.
<https://doi.org/10.1001/JAMA.2021.11330>

Hallquist, M.N., Hwang, K., Luna, B., 2013. The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity. *NeuroImage* 82, 208–25.
<https://doi.org/10.1016/j.neuroimage.2013.05.116>

Hanafi, R., Roger, P.-A., Perin, B., Kuchcinski, G., Deleval, N., Dallery, F., Michel, D., Hacein-Bey, L., Pruvo, J.-P., Outteryck, O., Constans, J.-M., 2020. COVID-19 Neurologic Complication with CNS Vasculitis-Like Pattern. *American Journal of Neuroradiology* 41, 1384–1387.
<https://doi.org/10.3174/AJNR.A6651>

Hansen, J.Y., Markello, R.D., Vogel, J.W., Seidlitz, J., Bzdok, D., Masic, B., 2021a. Mapping gene transcription and neurocognition across human neocortex. *Nature Human Behaviour* 2021 5:9 5, 1240–1250. <https://doi.org/10.1038/s41562-021-01082-z>

Hansen, J.Y., Shafiei, G., Markello, R.D., Smart, K., Cox, S.M.L., Wu, Y., Gallezot, J.-D., Aumont, É., Servaes, S., Scala, S.G., DuBois, J.M., Wainstein, G., Bezgin, G., Funck, T., Schmitz, T.W., Spreng, R.N., Soucy, J.-P., Baillet, S., Guimond, S., Hietala, J., Bédard, M.-A., Leyton, M., Kobayashi, E., Rosa-Neto, P., Palomero-Gallagher, N., Shine, J.M., Carson, R.E., Tuominen, L., Dagher, A., Masic, B., 2021b. Mapping neurotransmitter systems to the structural and functional organization of the human neocortex. *bioRxiv* 2021.10.28.466336. <https://doi.org/10.1101/2021.10.28.466336>

Hawrylycz, M.J., Lein, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L., Miller, J.A., van de Lagemaat, L.N., Smith, K.A., Ebbert, A., Riley, Z.L., Abajian, C., Beckmann, C.F., Bernard, A., Bertagnolli, D., Boe, A.F., Cartagena, P.M., Mallar Chakravarty, M., Chapin, M., Chong, J., Dalley, R.A., Daly, B.D., Dang, C., Datta, S., Dee, N., Dolbeare, T.A., Faber, V., Feng, D., Fowler, D.R., Goldy, J., Gregor, B.W., Haradon, Z., Haynor, D.R., Hohmann, J.G., Horvath, S., Howard, R.E., Jeromin, A., Jochim, J.M., Kinnunen, M., Lau, C., Lazarz, E.T., Lee, C., Lemon, T.A., Li, L., Li, Y., Morris, J.A., Overly, C.C., Parker, P.D., Parry, S.E., Reding, M., Royall, J.J., Schulkin, J., Sequeira, P.A., Slaughterbeck, C.R., Smith, S.C., Sodt, A.J., Sunkin, S.M., Swanson, B.E., Vawter, M.P., Williams, D., Wohnoutka, P., Ronald Zielke, H., Geschwind, D.H., Hof, P.R., Smith, S.M., Koch, C., Grant, S.G.N., Jones, A.R., 2012. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* 489, 391–399. <https://doi.org/10.1038/NATURE11405>

He, L., Mäe, M.A., Muhl, L., Sun, Y., Pietilä, R., Nahar, K., Liébanas, E.V., Fagerlund, M.J., Oldner, A., Liu, J., Genové, G., Zhang, L., Xie, Y., Leptidis, S., Mocci, G., Stritt, S., Osman, A., Anisimov, A., Hemanthakumar, K.A., Räsänen, M., Mirabeau, O., Hansson, E., Björkegren, J., Vanlandewijck, M., Blomgren, K., Mäkinen, T., Peng, X.R., Arnold, T.D., Alitalo, K., Eriksson, L.I., Lendahl, U.,

Betsholtz, C., 2020. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 – implications for microvascular inflammation and hypercoagulopathy in COVID-19. *bioRxiv* 2020.05.11.088500. <https://doi.org/10.1101/2020.05.11.088500>

Heijmans, L., Mons, M.R., Joosten, E.A., 2021. A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation. *Molecular pain* 17. <https://doi.org/10.1177/17448069211043965>

Hensley, M.K., Markantone, D., Prescott, H.C., 2021. Neurologic Manifestations and Complications of COVID-19. <https://doi.org/10.1146/annurev-med-042320-010427> 73. <https://doi.org/10.1146/ANNUREV-MED-042320-010427>

Hosp, J., Dressing, A., Blazhenets, G., Bormann, T., Rau, A., Schwabenland, M., Thurow, J., Wagner, D., Waller, C., Niesen, W., Frings, L., Urbach, H., Prinz, M., Weiller, C., Schroeter, N., Meyer, P., 2021. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. *Brain : a journal of neurology* 144, 1263–1276. <https://doi.org/10.1093/BRAIN/AWAB009>

Iadecola, C., Anrather, J., Kamel, H., 2020. Effects of COVID-19 on the Nervous System. *Cell* 183, 16. <https://doi.org/10.1016/J.CELL.2020.08.028>

Iba, T., Connors, J.M., Levy, J.H., 2020. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. *Inflammation Research* 2020 69:12 69, 1181–1189. <https://doi.org/10.1007/S00011-020-01401-6>

Jenkinson, M., Bannister, P., Brady, M., Smith, S., 2002. Improved optimization for the robust and accurate linear registration and motion correction of brain images. *NeuroImage* 17, 825–41.

Jensen, K.E., Thomsen, C., Henriksen, O., 1988. In vivo measurement of intracellular pH in human brain during different tensions of carbon dioxide in arterial blood. A ³¹P-NMR study. *Acta physiologica Scandinavica* 134, 295–8. <https://doi.org/10.1111/j.1748-1716.1988.tb08492.x>

Kakarla, V., Kaneko, N., Nour, M., Khatibi, K., Elahi, F., Liebeskind, D.S., Hinman, J.D., 2021. Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2: <https://doi.org/10.1177/0271678X20985666> 41, 1179–1192. <https://doi.org/10.1177/0271678X20985666>

Kaneko, N., Satta, S., Komuro, Y., Muthukrishnan, S.D., Kakarla, V., Guo, L., An, J., Elahi, F., Kornblum, H.I., Liebeskind, D.S., Hsiai, T., Hinman, J.D., 2021. Flow-Mediated Susceptibility and Molecular Response of Cerebral Endothelia to SARS-CoV-2 Infection. *Stroke* 260–270. <https://doi.org/10.1161/STROKEAHA.120.032764>

Kannurpatti, S.S., Biswal, B.B., 2008. Detection and scaling of task-induced fMRI-BOLD response using resting state fluctuations. *NeuroImage* 40, 1567–74.
<https://doi.org/10.1016/j.neuroimage.2007.09.040>

Keyeux, A., Ochrymowicz-Bemelmans, D., Charlier, A.A., 1995. Induced response to hypercapnia in the two-compartment total cerebral blood volume: influence on brain vascular reserve and flow efficiency. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 15, 1121–31.
<https://doi.org/10.1038/jcbfm.1995.139>

Khaddaj-Mallat, R., Aldib, N., Bernard, M., Paquette, A.-S., Ferreira, A., Lecordier, S., Saghatelian, A., Flamand, L., ElAli, A., 2021. SARS-CoV-2 deregulates the vascular and immune functions of brain pericytes via Spike protein. *Neurobiology of Disease* 161, 105561.
<https://doi.org/10.1016/J.NBD.2021.105561>

Kraha, A., Turner, H., Nimon, K., Zientek, L.R., Henson, R.K., 2012. Tools to Support Interpreting Multiple Regression in the Face of Multicollinearity. *Frontiers in Psychology* 3, 44.
<https://doi.org/10.3389/fpsyg.2012.00044>

Krishnan, A., Williams, L.J., McIntosh, A.R., Abdi, H., 2011. Partial Least Squares (PLS) methods for neuroimaging: A tutorial and review. *NeuroImage* 56, 455–475.
<https://doi.org/10.1016/j.neuroimage.2010.07.034>

Lambertsen, C.J., Semple, S.J.G., Smyth, M.G., Gelfand, R., 1961. H^+ and pCO_2 as chemical factors in respiratory and cerebral circulatory control. *Journal of Applied Physiology* 16, 473–484.
<https://doi.org/10.1152/jappl.1961.16.3.473>

Lassen, N.A., 1968. Brain extracellular pH: the main factor controlling cerebral blood flow. *Scandinavian journal of clinical and laboratory investigation* 22, 247–51.
<https://doi.org/10.3109/00365516809167060>

Ledoit, O., Wolf, M., 2004. A well-conditioned estimator for large-dimensional covariance matrices. *Journal of Multivariate Analysis* 88, 365–411. [https://doi.org/10.1016/S0047-259X\(03\)00096-4](https://doi.org/10.1016/S0047-259X(03)00096-4)

Lersy, F., Anheim, M., Willaume, T., Chammas, A., Brisset, J.-C., Ois Cotton, F., Kremer, S., 2021. Cerebral vasculitis of medium-sized vessels as a possible mechanism of brain damage in COVID-19 patients. *Journal of Neuroradiology* 48, 141–146.
<https://doi.org/10.1016/j.neurad.2020.11.004>

Levi, M., Thachil, J., Iba, T., Levy, J.H., 2020. Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology* 7, e438–e440. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)

- 819 Lindquist, M.A., Geuter, S., Wager, T.D., Caffo, B.S., 2019. Modular preprocessing pipelines can
820 reintroduce artifacts into fMRI data. *Human Brain Mapping* 40, 2358–2376.
821 <https://doi.org/10.1002/hbm.24528>
- 822 Liu, X., Tyler, L.K., Cam-CAN, Rowe, J.B., Tsvetanov, K.A., 2021. Multimodal fusion analysis of
823 functional, cerebrovascular and structural neuroimaging in healthy ageing subjects. *bioRxiv*
824 2021.12.22.473894. <https://doi.org/10.1101/2021.12.22.473894>
- 825 Luan, Y.Y., Yin, C.H., Yao, Y.M., 2021. Update Advances on C-Reactive Protein in COVID-19 and Other
826 Viral Infections. *Frontiers in Immunology* 12, 3153.
827 <https://doi.org/10.3389/FIMMU.2021.720363/BIBTEX>
- 828 Mahoney, F.I., Barthel, D.W., 1965. Barthel Index. *Maryland State Medical Journal* 61–65.
- 829 Makedonov, I., Black, S.E., Macintosh, B.J., 2013. BOLD fMRI in the white matter as a marker of aging
830 and small vessel disease. *PloS one* 8, e67652. <https://doi.org/10.1371/journal.pone.0067652>
- 831 Makedonov, I., Chen, J.J., Masellis, M., MacIntosh, B.J., 2016. Physiological fluctuations in white
832 matter are increased in Alzheimer’s disease and correlate with neuroimaging and cognitive
833 biomarkers. *Neurobiology of Aging* 37, 12–18.
834 <https://doi.org/10.1016/j.neurobiolaging.2015.09.010>
- 835 Marcic, M., Marcic, L., Marcic, B., Capkun, V., Vukojevic, K., 2021. Cerebral Vasoreactivity Evaluated by
836 Transcranial Color Doppler and Breath-Holding Test in Patients after SARS-CoV-2 Infection.
837 *Journal of personalized medicine* 11. <https://doi.org/10.3390/JPM11050379>
- 838 Marshall, J.C., Murthy, S., Diaz, J., Adhikari, N.K., Angus, D.C., Arabi, Y.M., Baillie, K., Bauer, M., Berry,
839 S., Blackwood, B., Bonten, M., Bozza, F., Brunkhorst, F., Cheng, A., Clarke, M., Dat, V.Q., Jong, M.
840 de, Denholm, J., Derde, L., Dunning, J., Feng, X., Fletcher, T., Foster, N., Fowler, R., Gobat, N.,
841 Gomersall, C., Gordon, A., Glueck, T., Harhay, M., Hodgson, C., Horby, P., Kim, Y., Kojan, R.,
842 Kumar, B., Laffey, J., Malvey, D., Martin-Loeches, I., McArthur, C., McAuley, D., McBride, S.,
843 McGuinness, S., Merson, L., Morpeth, S., Needham, D., Netea, M., Oh, M.-D., Phyu, S., Piva, S.,
844 Qiu, R., Salisu-Kabara, H., Shi, L., Shimizu, N., Sinclair, J., Tong, S., Turgeon, A., Uyeki, T.,
845 Veerdonk, F. van de, Webb, S., Williamson, P., Wolf, T., Zhang, J., 2020. A minimal common
846 outcome measure set for COVID-19 clinical research. *The Lancet Infectious Diseases* 20, e192–
847 e197. [https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7)
- 848 McGonagle, D., Bridgewood, C., Ramanan, A. V., Meaney, J.F.M., Watad, A., 2021. COVID-19 vasculitis
849 and novel vasculitis mimics. *The Lancet. Rheumatology* 3, e224. [https://doi.org/10.1016/S2665-9913\(20\)30420-3](https://doi.org/10.1016/S2665-9913(20)30420-3)
- 851 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Fagan, A.M., Morris, J.C., Balota, D.A., 2020a.
852 Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer’s

853 disease. *Neurobiology of Aging* 96, 233–245.
854 <https://doi.org/10.1016/J.NEUROBIOLAGING.2020.08.007>
855 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A., 2021. Evaluating
856 Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent
857 Variability. *Journal of cognitive neuroscience* 33, 279–302.
858 https://doi.org/10.1162/JOCN_A_01645
859 Millar, P.R., Petersen, S.E., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A.,
860 2020b. Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after
861 Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. *Cerebral*
862 *Cortex* 00, 1–16. <https://doi.org/10.1093/cercor/bhaa138>
863 Mitsikostas, D.D., Sanchez Del Rio, M., Waeber, C., 2002. 5-Hydroxytryptamine(1B/1D) and 5-
864 hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse
865 trigeminal nucleus caudalis. *Cephalalgia : an international journal of headache* 22, 384–394.
866 <https://doi.org/10.1046/J.1468-2982.2002.00382.X>
867 Mohkhedkar, M., Venigalla, S.S.K., Janakiraman, V., 2021. Autoantigens That May Explain
868 Postinfection Autoimmune Manifestations in Patients With Coronavirus Disease 2019 Displaying
869 Neurological Conditions. *The Journal of Infectious Diseases* 223, 536–537.
870 <https://doi.org/10.1093/INFDIS/JIAA703>
871 Nair, V.A., Raut, R. V., Prabhakaran, V., 2017. Investigating the Blood Oxygenation Level-Dependent
872 Functional MRI Response to a Verbal Fluency Task in Early Stroke before and after
873 Hemodynamic Scaling. *Frontiers in Neurology* 8, 283. <https://doi.org/10.3389/fneur.2017.00283>
874 Nasreddine, Z., Phillips, N., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.,
875 Chertkow, H., 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild
876 cognitive impairment. *Journal of the American Geriatrics Society* 53, 695–699.
877 <https://doi.org/10.1111/J.1532-5415.2005.53221.X>
878 Newcombe, V.F.J., Spindler, L.R.B., Das, T., Winzeck, S., Allinson, K., Stamatakis, E.A., Menon, D.K.,
879 2020. Neuroanatomical substrates of generalized brain dysfunction in COVID-19. *Intensive Care*
880 *Medicine* 2020 47:1 47, 116–118. <https://doi.org/10.1007/S00134-020-06241-W>
881 Nilsson, T., Longmore, J., Shaw, D., Jansen Olesen, I.J., Edvinsson, L., 1999. Contractile 5-HT1B
882 receptors in human cerebral arteries: pharmacological characterization and localization with
883 immunocytochemistry. *British Journal of Pharmacology* 128, 1133–1140.
884 <https://doi.org/10.1038/SJ.BJP.0702773>

885 Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008a. An R package to compute commonality
886 coefficients in the multiple regression case: An introduction to the package and a practical
887 example. Behavior Research Methods 40, 457–466. <https://doi.org/10.3758/BRM.40.2.457>

888 Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008b. An R package to compute commonality
889 coefficients in the multiple regression case: An introduction to the package and a practical
890 example. Behavior Research Methods 40, 457–466. <https://doi.org/10.3758/BRM.40.2.457>

891 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su,
892 L., O'Brien, J.T., Rowe, J.B., 2019a. Neuroinflammation and functional connectivity in Alzheimer's
893 disease: interactive influences on cognitive performance. The Journal of Neuroscience 39, 2574–
894 18. <https://doi.org/10.1523/jneurosci.2574-18.2019>

895 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su,
896 L., O'Brien, J.T., Rowe, J.B., 2019b. Neuroinflammation and Functional Connectivity in
897 Alzheimer's Disease: Interactive Influences on Cognitive Performance. The Journal of
898 neuroscience : the official journal of the Society for Neuroscience 39.
899 <https://doi.org/10.1523/JNEUROSCI.2574-18.2019>

900 Paterson, R., Brown, R., Benjamin, L., Nortley, R., S, W., T, B., DL, J., G, K., RE, R., L, Z., V, V., A, K., R, G.,
901 K, C., E, B., H, T., G, P., G, C., J, M., P, M., B, M., ST, L., PR, M., V, L., S, K., W, Y., SA, T., AJM, F., G,
902 H., TD, M., AD, E., C, C., NWS, D., M, Y., D, A., J, Sreedharan, E, S., JM, S., A, Chandratheva, RJ, P.,
903 R, S., A, Checkley, N, L., SF, F., F, C., C, Houlihan, M, T., MP, L., J, Spillane, R, H., A, V., DJ, W., C,
904 Hoskote, Jäger HR, Manji, H., Zandi, M., 2020. The emerging spectrum of COVID-19 neurology:
905 clinical, radiological and laboratory findings. Brain : a journal of neurology 143, 3104–3120.
906 <https://doi.org/10.1093/BRAIN/AWAA240>

907 PL, E., MA, M., V, B., RP, T., R, M., A, A., AB, N., 2003. The 6-min walk test: a quick measure of
908 functional status in elderly adults. Chest 123, 387–398.
909 <https://doi.org/10.1378/CHEST.123.2.387>

910 Pruim, R.H.R., Mennes, M., Buitelaar, J.K., Beckmann, C.F., 2015a. Evaluation of ICA-AROMA and
911 alternative strategies for motion artifact removal in resting state fMRI. NeuroImage 112, 278–
912 287. <https://doi.org/10.1016/j.neuroimage.2015.02.063>

913 Pruim, R.H.R., Mennes, M., van Rooij, D., Llera, A., Buitelaar, J.K., Beckmann, C.F., 2015b. ICA-AROMA:
914 A robust ICA-based strategy for removing motion artifacts from fMRI data. NeuroImage 112,
915 267–277. <https://doi.org/10.1016/j.neuroimage.2015.02.064>

916 Raut, R. V., Nair, V.A., Sattin, J.A., Prabhakaran, V., 2016. Hypercapnic evaluation of vascular reactivity
917 in healthy aging and acute stroke via functional MRI. NeuroImage: Clinical 12, 173–179.
918 <https://doi.org/10.1016/j.nicl.2016.06.016>

Rorden, C., Brett, M., 2000. Stereotaxic display of brain lesions. Behavioural neurology 12, 191–200.
<https://doi.org/10.1155/2000/421719>

Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Ring, P.B., Henriksen, O., 1996. Susceptibility Contrast Imaging of CO₂-Induced Changes in the Blood Volume of the Human Brain. Acta Radiologica 37, 813–822. <https://doi.org/10.3109/02841859609177722>

Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Thomsen, C., Ring, P., Søndergaard, L., Henriksen, O., 1994. Functional MRI of CO₂ induced increase in cerebral perfusion. NMR in Biomedicine 7, 29–34. <https://doi.org/10.1002/nbm.1940070106>

Satterthwaite, T.D., Elliott, M. a, Gerraty, R.T., Ruparel, K., Loughhead, J., Calkins, M.E., Eickhoff, S.B., Hakonarson, H., Gur, R.C.R.E., Gur, R.C.R.E., Wolf, D.H., 2013. An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. NeuroImage 64, 240–56.
<https://doi.org/10.1016/j.neuroimage.2012.08.052>

Schnaubelt, S., Oppenauer, J., Tihanyi, D., Mueller, M., Maldonado-Gonzalez, E., Zejnilovic, S., Haslacher, H., Perkmann, T., Strassl, R., Anders, S., Stefenelli, T., Zehetmayer, S., Koppensteiner, R., Domanovits, H., Schlager, O., 2021. Arterial stiffness in acute COVID-19 and potential associations with clinical outcome. Journal of internal medicine 290, 437–443.
<https://doi.org/10.1111/JOIM.13275>

Shi, Y., Thrippleton, M.J., Makin, S.D., Marshall, I., Geerlings, M.I., de Craen, A.J.M., van Buchem, M.A., Wardlaw, J.M., 2016. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 36, 1653–1667.
<https://doi.org/10.1177/0271678X16662891>

Sibille, E., Su, J., Leman, S., le Guisquet, A.M., Ibarguen-Vargas, Y., Joeyen-Waldorf, J., Glorioso, C., Tseng, G.C., Pezzone, M., Hen, R., Belzung, C., 2007. Lack of serotonin1B receptor expression leads to age-related motor dysfunction, early onset of brain molecular aging and reduced longevity. Molecular psychiatry 12, 1042–1056. <https://doi.org/10.1038/SJ.MP.4001990>

Tsvetanov, K.A., Gazzina, S., Jones, P.S., Swieten, J., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce, R., Graff, C., Synofzik, M., Galimberti, D., Masellis, M., Tartaglia, M.C., Finger, E., Vandenberghe, R., Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C., Gerhard, A., Danek, A., Levin, J., Otto, M., Frisoni, G., Ghidoni, R., Sorbi, S., Rohrer, J.D., Rowe, J.B., 2020a. Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's & Dementia alz.12209.
<https://doi.org/10.1002/alz.12209>

- 953 Tsvetanov, K.A., Henson, R.N.A., Jones, P.S., Mutsaerts, H., Fuhrmann, D., Tyler, L.K., Rowe, J.B.,
954 2020b. The effects of age on resting-state BOLD signal variability is explained by cardiovascular
955 and cerebrovascular factors, in: Psychophysiology. Blackwell Publishing Inc.
956 <https://doi.org/10.1111/psyp.13714>
- 957 Tsvetanov, K.A., Henson, R.N.A., Rowe, J.B., 2020c. Separating vascular and neuronal effects of age on
958 fMRI BOLD signals. Philosophical Transactions of the Royal Society B: Biological Sciences.
959 <https://doi.org/10.1098/rstb.2019.0631>
- 960 Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Davis, S.W., Shafto, M.A., Taylor, J.R., Williams, N., Rowe,
961 J.B., 2015. The effect of ageing on fMRI: Correction for the confounding effects of vascular
962 reactivity evaluated by joint fMRI and MEG in 335 adults. Human Brain Mapping 36, 2248–2269.
963 <https://doi.org/10.1002/hbm.22768>
- 964 Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Razi, A., Geerligs, L., Ham, T.E., Rowe, J.B., 2016. Extrinsic
965 and intrinsic brain network connectivity maintains cognition across the lifespan despite
966 accelerated decay of regional brain activation. Journal of Neuroscience 36, 3115–26.
967 <https://doi.org/10.1523/JNEUROSCI.2733-15.2016>
- 968 Tsvetanov, K.A., Ye, Z., Hughes, L., Samu, D., Treder, M.S., Wolpe, N., Tyler, L.K., Rowe, J.B., for
969 Cambridge Centre for Ageing and Neuroscience, 2018. Activity and connectivity differences
970 underlying inhibitory control across the adult lifespan. The Journal of neuroscience : the official
971 journal of the Society for Neuroscience 38, 7887–7900.
972 <https://doi.org/10.1523/JNEUROSCI.2919-17.2018>
- 973 Ulhaq, Z.S., Soraya, G.V., 2020. Interleukin-6 as a potential biomarker of COVID-19 progression.
974 Médecine et Maladies Infectieuses 50, 382–383.
975 <https://doi.org/10.1016/J.MEDMAL.2020.04.002>
- 976 Vaishnavi, S.N., Vlassenko, A.G., Rundle, M.M., Snyder, A.Z., Mintun, M.A., Raichle, M.E., 2010.
977 Regional aerobic glycolysis in the human brain. Proceedings of the National Academy of Sciences
978 of the United States of America 107, 17757–17762.
979 <https://doi.org/10.1073/PNAS.1010459107/-/DCSUPPLEMENTAL>
- 980 Váša, F., Seidlitz, J., Romero-Garcia, R., Whitaker, K.J., Rosenthal, G., Vértes, P.E., Shinn, M.,
981 Alexander-Bloch, A., Fonagy, P., Dolan, R.J., Jones, P.B., Goodyer, I.M., Sporns, O., Bullmore, E.T.,
982 2018. Adolescent Tuning of Association Cortex in Human Structural Brain Networks. Cerebral
983 cortex (New York, N.Y. : 1991) 28, 281–294. <https://doi.org/10.1093/CERCOR/BHX249>
- 984 Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G.,
985 Thompson, H., Walker, P.G.T., Fu, H., Dighe, A., Griffin, J.T., Baguelin, M., Bhatia, S., Boonyasiri,
986 A., Cori, A., Cucunubá, Z., FitzJohn, R., Gaythorpe, K., Green, W., Hamlet, A., Hinsley, W., Laydon,

987 D., Nedjati-Gilani, G., Riley, S., van Elsland, S., Volz, E., Wang, H., Wang, Y., Xi, X., Donnelly, C.A.,
988 Ghani, A.C., Ferguson, N.M., 2020. Estimates of the severity of coronavirus disease 2019: a
989 model-based analysis. *The Lancet Infectious Diseases* 20, 669–677.
990 [https://doi.org/10.1016/S1473-3099\(20\)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-](https://doi.org/10.1016/S1473-3099(20)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-FC2C52BBAFD7/MMC1.PDF)
991 [FC2C52BBAFD7/MMC1.PDF](https://doi.org/10.1016/S1473-3099(20)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-FC2C52BBAFD7/MMC1.PDF)

992 Vestergaard, M.B., Jensen, M.L.F., Arnglim, N., Lindberg, U., Larsson, H.B.W., 2020. Higher
993 physiological vulnerability to hypoxic exposure with advancing age in the human brain. *Journal*
994 *of Cerebral Blood Flow & Metabolism* 40, 341. <https://doi.org/10.1177/0271678X18818291>

995 Vlassenko, A.G., Vaishnavi, S.N., Couture, L., Sacco, D., Shannon, B.J., Mach, R.H., Morris, J.C., Raichle,
996 M.E., Mintun, M.A., 2010. Spatial correlation between brain aerobic glycolysis and amyloid- β (A β
997) deposition. *Proceedings of the National Academy of Sciences of the United States of America*
998 107, 17763–17767. <https://doi.org/10.1073/PNAS.1010461107>

999 Vos de Wael, R., Benkarim, O., Paquola, C., Lariviere, S., Royer, J., Tavakol, S., Xu, T., Hong, S.J., Langs,
1000 G., Valk, S., Mistic, B., Milham, M., Margulies, D., Smallwood, J., Bernhardt, B.C., 2020.
1001 BrainSpace: a toolbox for the analysis of macroscale gradients in neuroimaging and
1002 connectomics datasets. *Communications Biology* 2020 3:1 3, 1–10.
1003 <https://doi.org/10.1038/s42003-020-0794-7>

1004 Wagerle, L.C., Mishra, O.P., 1988. Mechanism of CO₂ response in cerebral arteries of the newborn
1005 pig: Role of phospholipase, cyclooxygenase, and lipoxygenase pathways. *Circulation Research*
1006 62, 1019–1026. <https://doi.org/10.1161/01.RES.62.5.1019>

1007 Willie, C.K., Tzeng, Y.-C., Fisher, J.A., Ainslie, P.N., 2014. Integrative regulation of human brain blood
1008 flow. *The Journal of physiology* 592, 841–59. <https://doi.org/10.1113/jphysiol.2013.268953>

1009 Wool, G.D., Miller, J.L., 2021. The Impact of COVID-19 Disease on Platelets and Coagulation.
1010 *Pathobiology* 88, 15–27. <https://doi.org/10.1159/000512007>

1011 Wu, S., Tyler, L.K., Rowe, J.B., Cam-CAN, Tsvetanov, K.A., 2021. Brain cerebral blood flow explains
1012 behaviour-relevant BOLD responses in fluid ability across the lifespan. In Preparation.

1013 Xu, L., Groth, K.M., Pearlson, G., Schretlen, D.J., Calhoun, V.D., 2009. Source-based morphometry: the
1014 use of independent component analysis to identify gray matter differences with application to
1015 schizophrenia. *Human brain mapping* 30, 711–24. <https://doi.org/10.1002/hbm.20540>

1016 Yang, A.C., Vest, R.T., Kern, F., Lee, D.P., Maat, C.A., Losada, P.M., Chen, M.B., Agam, M., Schaum, N.,
1017 Khoury, N., Calcuttawala, K., Pálovics, R., Shin, A., Wang, E.Y., Luo, J., Gate, D., Siegenthaler, J.A.,
1018 McNerney, M.W., Keller, A., Wyss-Coray, T., 2021. A human brain vascular atlas reveals diverse
1019 cell mediators of Alzheimer’s disease risk. *bioRxiv* 2021.04.26.441262.
1020 <https://doi.org/10.1101/2021.04.26.441262>

1021 Zhang, X.J., Qin, J.J., Cheng, X., Shen, L., Zhao, Y.C., Yuan, Y., Lei, F., Chen, M.M., Yang, H., Bai, L., Song,
1022 X., Lin, L., Xia, M., Zhou, F., Zhou, J., She, Z.G., Zhu, L., Ma, X., Xu, Q., Ye, P., Chen, G., Liu, L., Mao,
1023 W., Yan, Y., Xiao, B., Lu, Z., Peng, G., Liu, M., Yang, Jun, Yang, L., Zhang, C., Lu, H., Xia, X., Wang,
1024 D., Liao, X., Wei, X., Zhang, B.H., Zhang, X., Yang, Juan, Zhao, G.N., Zhang, P., Liu, P.P., Loomba,
1025 R., Ji, Y.X., Xia, J., Wang, Y., Cai, J., Guo, J., Li, H., 2020. In-Hospital Use of Statins Is Associated
1026 with a Reduced Risk of Mortality among Individuals with COVID-19. Cell metabolism 32, 176-
1027 187.e4. <https://doi.org/10.1016/J.CMET.2020.06.015>
1028 Zubair, A.S., McAlpine, L.S., Gardin, T., Farhadian, S., Kuruvilla, D.E., Spudich, S., 2020.
1029 Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of
1030 Coronavirus Disease 2019: A Review. JAMA Neurology 77, 1018–1027.
1031 <https://doi.org/10.1001/JAMANEUROL.2020.2065>
1032